Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Acquired hemophilia is a bleeding disorder that interferes with the body's blood clotting process. Signs and symptoms include prolonged bleeding, frequent nosebleeds, bruising throughout the body, solid swellings of congealed blood (hematomas), hematuria, and gastrointestinal or urologic bleeding. Acquired hemophilia occurs when the body's immune system attacks and disables a certain protein that helps the blood clot. About half of the cases are associated with other conditions, such as pregnancy, autoimmune disease, cancer, skin diseases, or allergic reactions to medications.
Biomarker and diagnostic research for acquired hemophilia has been reported in the published literature.
5 clinical trials registered, 3 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE4, 1 PHASE2, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05345197](https://clinicaltrials.gov/study/NCT05345197) |
Data assembled from 4 of 12 sources · Last updated Oct 4, 2026, 6:17 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acquired hemophilia
Emicizumab in Patients With Acquired Hemophilia A
PHASE2 |
University of Washington |
ACTIVE_NOT_RECRUITING |
[NCT06461533](https://clinicaltrials.gov/study/NCT06461533) | A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A | — | Takeda | RECRUITING |
[NCT05849740](https://clinicaltrials.gov/study/NCT05849740) | An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A | PHASE4 | Institute of Hematology & Blood Diseases Hospital, China | RECRUITING |
[NCT06550882](https://clinicaltrials.gov/study/NCT06550882) | A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea | — | Takeda | RECRUITING |
[NCT07789587](https://clinicaltrials.gov/study/NCT07789587) | A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A | NA | Institute of Hematology & Blood Diseases Hospital, China | NOT_YET_RECRUITING |
212 publications have been identified in PubMed for acquired hemophilia. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (16%), and Epidemiology / Natural History (8%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 106 | 50% |
Research summaries | 34 | 16% |
Disease patterns and progression | 18 | 8% |
Clinical study results | 17 | 8% |
Laboratory research | 10 | 5% |
Other research | 9 | 4% |
Testing and diagnosis research | 9 | 4% |
New treatment approaches | 9 | 4% |
Tufano A (2026). [PMID: 41802449](https://pubmed.ncbi.nlm.nih.gov/41802449/). *Seminars in thrombosis and hemostasis*. [Epidemiology / Natural History]
Timmerije R (2026). [PMID: 41624237](https://pubmed.ncbi.nlm.nih.gov/41624237/). *Res Pract Thromb Haemost*. [Diagnostic / Biomarker]
Perrone S (2026). [PMID: 42105103](https://pubmed.ncbi.nlm.nih.gov/42105103/). *Ann Hematol*. [Epidemiology / Natural History]
Kulikov S (2026). [PMID: 41676353](https://pubmed.ncbi.nlm.nih.gov/41676353/). *Res Pract Thromb Haemost*. [Other]
Franchini M (2026). [PMID: 40341996](https://pubmed.ncbi.nlm.nih.gov/40341996/). *Seminars in thrombosis and hemostasis*. [Epidemiology / Natural History]
Capponi A (2026). [PMID: 42199775](https://pubmed.ncbi.nlm.nih.gov/42199775/). *World J Emerg Med*. [Case Report / Case Series]
Gurumurthy G (2026). [PMID: 40925410](https://pubmed.ncbi.nlm.nih.gov/40925410/). *Seminars in thrombosis and hemostasis*. [Other]
Bettonville L (2026). [PMID: 41815023](https://pubmed.ncbi.nlm.nih.gov/41815023/). *Rev Med Liege*. [Case Report / Case Series]
Pastore G (2026). [PMID: 40527348](https://pubmed.ncbi.nlm.nih.gov/40527348/). *Seminars in thrombosis and hemostasis*. [Clinical Trial Publication]
Muradashvili T (2026). [PMID: 41926332](https://pubmed.ncbi.nlm.nih.gov/41926332/). *Expert Rev Hematol*. [Review / Meta-Analysis]
AI-curated news mentioning acquired hemophilia
Updated Sep 2, 2026
A multicenter real-life study provides new insights into acquired hemophilia, highlighting its prevalence and management in a middle-income country. The findings may inform future treatment strategies and improve patient outcomes.
A recent case report highlights the complexities of acquired hemophilia A, detailing instances of hematoma, hemarthrosis, and hemotympanum. This study contributes to the understanding of the clinical manifestations associated with this rare bleeding disorder.
A recent cost-effectiveness analysis evaluates the use of emicizumab in hospitalized older patients with acquired hemophilia A. The study provides insights into the economic implications of this treatment option for a vulnerable patient population.